Qiang Wu1, Wuxia Luo, Yaqin Zhao, Feng Xu, Qinghua Zhou. 1. aLung Cancer Center bDepartment of Abdominal Cancer, Cancer Center, West China Hospital, Sichuan University cDepartment of Medical Oncology, the First People's Hospital of Chengdu, Chengdu, China.
Abstract
OBJECTIVES: The aim of the present meta-analysis was to systematically evaluate the overall diagnostic accuracy of F-FDG PET/CT for the detection of adrenal metastasis in lung cancer. PATIENTS AND METHODS: A comprehensive literature search of Medline (PubMed), Embase, Web of Science, Cochrane, and China National Knowledge Infrastructure databases published through 10 January 2017 on the role of F-FDG PET/CT in evaluating adrenal mass in lung cancer patients was performed. Pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of F-FDG PET/CT on a per lesion-based analysis were calculated. The area under the curve was calculated to measure the accuracy of F-FDG PET/CT. RESULTS: A total of nine studies, involving 707 lung cancer patients with 810 adrenal masses, were included in the present meta-analysis. Of 810 adrenal masses from lung cancer, 411 (50.7%) and 399 (49.3%) masses were benign and metastatic, respectively. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of F-FDG PET/CT were 0.887 [95% confidence interval (CI): 0.852-0.917], 0.908 (95% CI: 0.875-0.934), 8.552 (95% CI: 6.197-11.802), 0.090 (95% CI: 0.039-0.211), and 96.825 (95% CI: 40.402-232.05), respectively. In addition, the area under the curve was 0.9622 and the overall diagnostic accuracy (Q* index) was 0.9077, suggesting excellent performance. CONCLUSION: F-FDG PET/CT plays a vital role in the differentiation of adrenal metastasis from a benign adrenal mass in lung cancer patients, with excellent diagnostic performance.
OBJECTIVES: The aim of the present meta-analysis was to systematically evaluate the overall diagnostic accuracy of F-FDG PET/CT for the detection of adrenal metastasis in lung cancer. PATIENTS AND METHODS: A comprehensive literature search of Medline (PubMed), Embase, Web of Science, Cochrane, and China National Knowledge Infrastructure databases published through 10 January 2017 on the role of F-FDG PET/CT in evaluating adrenal mass in lung cancerpatients was performed. Pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of F-FDG PET/CT on a per lesion-based analysis were calculated. The area under the curve was calculated to measure the accuracy of F-FDG PET/CT. RESULTS: A total of nine studies, involving 707 lung cancerpatients with 810 adrenal masses, were included in the present meta-analysis. Of 810 adrenal masses from lung cancer, 411 (50.7%) and 399 (49.3%) masses were benign and metastatic, respectively. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of F-FDG PET/CT were 0.887 [95% confidence interval (CI): 0.852-0.917], 0.908 (95% CI: 0.875-0.934), 8.552 (95% CI: 6.197-11.802), 0.090 (95% CI: 0.039-0.211), and 96.825 (95% CI: 40.402-232.05), respectively. In addition, the area under the curve was 0.9622 and the overall diagnostic accuracy (Q* index) was 0.9077, suggesting excellent performance. CONCLUSION:F-FDG PET/CT plays a vital role in the differentiation of adrenal metastasis from a benign adrenal mass in lung cancerpatients, with excellent diagnostic performance.
Authors: Domenico Albano; Francesco Agnello; Federico Midiri; Giusy Pecoraro; Alberto Bruno; Pierpaolo Alongi; Patrizia Toia; Giuseppe Di Buono; Antonino Agrusa; Luca Maria Sconfienza; Salvatore Pardo; Ludovico La Grutta; Massimo Midiri; Massimo Galia Journal: Insights Imaging Date: 2019-01-25